Several pharmaceutical companies have faced setbacks in their drug development programs. Replimune's skin cancer therapy and Merck KGaA's experimental multiple-sclerosis drug, evobrutinib, failed in mid and late-stage trials respectively. Additionally, a major human trial of an experimental drug aimed at protecting the brain after stroke has been paused by the National Institutes of Health. The failure of these trials has significant implications for the companies and the healthcare sector as a whole.
PrEPVacc was one of the first large, African-led HIV vaccine trials and one of the first trials to incorporate PrEP. Now it's shutting down, and no other vaccine trials are… https://t.co/yuemDxVMeD
Merck KGaA: MS drug failure is a sour note for growth hopes https://t.co/NxW2u7ljDY | opinion
In January I reported for @NBCNews on yet another failure of a major HIV vaccine trial. At the time, I noted that 1 major trial was ongoing. Today, that trial's leaders announced it "has stopped further vaccinations as there is little or no chance of the trial demonstrating… https://t.co/d1FmwnmxCQ
Merck KGaA’s BTK drug flunks pivotal multiple sclerosis trials, sending shockwaves through the sector https://t.co/psbmfJz4E4
The National Institutes of Health has paused the start of a major human trial of an experimental drug aimed at protecting the brain after stroke. https://t.co/7ZUUotrb4H
PEPFAR, a health program to fight HIV/AIDS, has yet to be reauthorized by the U.S. Congress. "Scientists, health care experts, global health leaders, and advocates must stand up at this critical moment," argued a recent #ScienceEditorial. https://t.co/f2nKRmtMiL https://t.co/9LZ4bsvTPq
Merck KGaA says MS drug fails in late-stage trials https://t.co/s9HcMfoP0v https://t.co/V0tVxPdBfm
German pharmaceutical company Merck KGaA said its experimental multiple-sclerosis drug evobrutinib failed in late-stage trials — a blow for its aspirations of creating a blockbuster medicine https://t.co/z88PJo4KJq
Replimune's skin cancer therapy fails in mid-stage study, shares plunge https://t.co/xVRaskeSXJ https://t.co/mHpzsmDIkc